ArticleFrontiers in oncology2026
Management challenges in metachronous bilateral breast cancer with discordant receptor status: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bilateral breast cancer is uncommon, accounting for 2%-5% of cases, and presents additional clinical challenges when tumors exhibit discordant molecular subtypes. Metachronous tumors, occurring sequentially, require individualized therapeutic strategies, especially when one tumor is triple-negative and the other is hormone-responsive. Case presentation: We report on a 37-year-old woman who initially presented with a left-sided breast lump during her fifth pregnancy. Histopathology revealed invasive carcinoma of no special type (NST), progesterone receptor (PR)-positive (90%), estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-negative, with a high proliferative index (Ki-67 = 90%), staged T2N2M0 (stage IIB/IIIA). Subsequently, she developed a right-sided breast mass, confirmed as triple-negative invasive carcinoma (T4N3M0, stage IIIC). The patient was initiated on neoadjuvant chemotherapy with the adriamycin and cyclophosphamide (AC) regimen and received supportive care, including ondansetron, morphine, and bisacodyl. Her Eastern Cooperative Oncology Group (ECOG) performance status was 1, and she experienced significant weight loss (from 68 to 46 kg in 4 months). Post-chemotherapy imaging will guide surgical planning. Discussion: This case highlights the rarity and complexity of metachronous bilateral breast cancer with discordant receptor status. Therapeutic prioritization is guided by the more aggressive tumor, in this instance, the triple-negative carcinoma, while simultaneously addressing the hormone-responsive lesion. Neoadjuvant chemotherapy allows tumor downstaging, assessment of chemosensitivity, and individualized surgical planning. Multidisciplinary management is essential to optimize outcomes and address prognostic variability between tumors. Conclusion: Metachronous bilateral breast cancer with discordant molecular subtypes presents significant diagnostic and management challenges. Individualized, biology-driven treatment strategies are critical, emphasizing the importance of systemic therapy guided by the more aggressive tumor and careful post-chemotherapy surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.